Changes in HER2 expression and amplification status following preoperative chemotherapy for gastric cancer

Sei Shu, Makoto Iimori, Ryota Nakanishi, Tomoko Jogo, Hiroshi Saeki, Eiji Oki, Yoshihiko Maehara

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: It is essential to establish a strategy for second-line treatment for human epidermal growth factor receptor 2 (HER2)-positive gastric cancer; however, HER2 expression status after chemotherapy treatment is not routinely determined. Materials and Methods: We analyzed 25 cases of gastric cancer that received preoperative chemotherapy and selected the six pre-treatment samples that were HER2- positive. Pre- and post-treatment tumor samples were examined for HER2 expression, and for HER2, epidermal growth factor receptor (EGFR), and hepatocyte growth factor receptor (MET) gene amplification. Results: Three patients had been treated with trastuzumab plus chemotherapy, and three patients with cytotoxic chemotherapy alone. Only one case that had an initial HER2 score of 3+ and had received trastuzumab plus chemotherapy remained HER2-positive after treatment. Decrease or loss of HER2 expression and amplification was observed in the other five patients. Amplification of EGFR or MET was not observed in any preor post-treatment specimens. Conclusion: Our data suggest that trastuzumab plus chemotherapy or chemotherapy alone may induce loss of HER2 positivity.

Original languageEnglish
Pages (from-to)1491-1498
Number of pages8
JournalIn Vivo
Volume32
Issue number6
DOIs
Publication statusPublished - Nov 1 2018

Fingerprint

Chemotherapy
Stomach Neoplasms
Amplification
Drug Therapy
Epidermal Growth Factor Receptor
Therapeutics
Proto-Oncogene Proteins c-met
human ERBB2 protein
Gene Amplification
Tumors

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology

Cite this

Changes in HER2 expression and amplification status following preoperative chemotherapy for gastric cancer. / Shu, Sei; Iimori, Makoto; Nakanishi, Ryota; Jogo, Tomoko; Saeki, Hiroshi; Oki, Eiji; Maehara, Yoshihiko.

In: In Vivo, Vol. 32, No. 6, 01.11.2018, p. 1491-1498.

Research output: Contribution to journalArticle

Shu, Sei ; Iimori, Makoto ; Nakanishi, Ryota ; Jogo, Tomoko ; Saeki, Hiroshi ; Oki, Eiji ; Maehara, Yoshihiko. / Changes in HER2 expression and amplification status following preoperative chemotherapy for gastric cancer. In: In Vivo. 2018 ; Vol. 32, No. 6. pp. 1491-1498.
@article{fa68473c5be644278866047cff072a07,
title = "Changes in HER2 expression and amplification status following preoperative chemotherapy for gastric cancer",
abstract = "Background: It is essential to establish a strategy for second-line treatment for human epidermal growth factor receptor 2 (HER2)-positive gastric cancer; however, HER2 expression status after chemotherapy treatment is not routinely determined. Materials and Methods: We analyzed 25 cases of gastric cancer that received preoperative chemotherapy and selected the six pre-treatment samples that were HER2- positive. Pre- and post-treatment tumor samples were examined for HER2 expression, and for HER2, epidermal growth factor receptor (EGFR), and hepatocyte growth factor receptor (MET) gene amplification. Results: Three patients had been treated with trastuzumab plus chemotherapy, and three patients with cytotoxic chemotherapy alone. Only one case that had an initial HER2 score of 3+ and had received trastuzumab plus chemotherapy remained HER2-positive after treatment. Decrease or loss of HER2 expression and amplification was observed in the other five patients. Amplification of EGFR or MET was not observed in any preor post-treatment specimens. Conclusion: Our data suggest that trastuzumab plus chemotherapy or chemotherapy alone may induce loss of HER2 positivity.",
author = "Sei Shu and Makoto Iimori and Ryota Nakanishi and Tomoko Jogo and Hiroshi Saeki and Eiji Oki and Yoshihiko Maehara",
year = "2018",
month = "11",
day = "1",
doi = "10.21873/invivo.11405",
language = "English",
volume = "32",
pages = "1491--1498",
journal = "In Vivo",
issn = "0258-851X",
publisher = "International Institute of Anticancer Research",
number = "6",

}

TY - JOUR

T1 - Changes in HER2 expression and amplification status following preoperative chemotherapy for gastric cancer

AU - Shu, Sei

AU - Iimori, Makoto

AU - Nakanishi, Ryota

AU - Jogo, Tomoko

AU - Saeki, Hiroshi

AU - Oki, Eiji

AU - Maehara, Yoshihiko

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Background: It is essential to establish a strategy for second-line treatment for human epidermal growth factor receptor 2 (HER2)-positive gastric cancer; however, HER2 expression status after chemotherapy treatment is not routinely determined. Materials and Methods: We analyzed 25 cases of gastric cancer that received preoperative chemotherapy and selected the six pre-treatment samples that were HER2- positive. Pre- and post-treatment tumor samples were examined for HER2 expression, and for HER2, epidermal growth factor receptor (EGFR), and hepatocyte growth factor receptor (MET) gene amplification. Results: Three patients had been treated with trastuzumab plus chemotherapy, and three patients with cytotoxic chemotherapy alone. Only one case that had an initial HER2 score of 3+ and had received trastuzumab plus chemotherapy remained HER2-positive after treatment. Decrease or loss of HER2 expression and amplification was observed in the other five patients. Amplification of EGFR or MET was not observed in any preor post-treatment specimens. Conclusion: Our data suggest that trastuzumab plus chemotherapy or chemotherapy alone may induce loss of HER2 positivity.

AB - Background: It is essential to establish a strategy for second-line treatment for human epidermal growth factor receptor 2 (HER2)-positive gastric cancer; however, HER2 expression status after chemotherapy treatment is not routinely determined. Materials and Methods: We analyzed 25 cases of gastric cancer that received preoperative chemotherapy and selected the six pre-treatment samples that were HER2- positive. Pre- and post-treatment tumor samples were examined for HER2 expression, and for HER2, epidermal growth factor receptor (EGFR), and hepatocyte growth factor receptor (MET) gene amplification. Results: Three patients had been treated with trastuzumab plus chemotherapy, and three patients with cytotoxic chemotherapy alone. Only one case that had an initial HER2 score of 3+ and had received trastuzumab plus chemotherapy remained HER2-positive after treatment. Decrease or loss of HER2 expression and amplification was observed in the other five patients. Amplification of EGFR or MET was not observed in any preor post-treatment specimens. Conclusion: Our data suggest that trastuzumab plus chemotherapy or chemotherapy alone may induce loss of HER2 positivity.

UR - http://www.scopus.com/inward/record.url?scp=85055178599&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055178599&partnerID=8YFLogxK

U2 - 10.21873/invivo.11405

DO - 10.21873/invivo.11405

M3 - Article

VL - 32

SP - 1491

EP - 1498

JO - In Vivo

JF - In Vivo

SN - 0258-851X

IS - 6

ER -